安微徽医科大学国际教育学院教案与讲稿 5.Ismail,R.Teh,LK.The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients.J Clin Pharm Ther 2006;31.99-109 6.Karas-Kuzelicki,N.Jazbec,J.Milek,M.Mlinaric-Rascan,I. Heterozygosity at the TPMT gene locus,augmented by mutated MTHFR gene,predisposes to 6-MP related toxicities in childhood ALL patients. Leukemia2009:23,971-974 7.Ingelman-Sundberg,M.Pharmacogenetics of cytochrome P450 and its applications in drug therapy:the past,present and future.Trends Pharmacol Sci2004;25,193-200 Memo 2安徽医科大学国际教育学院教案与讲稿 2 5. Ismail, R. Teh, LK. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. J Clin Pharm Ther 2006; 31. 99-109 6. Karas-Kuzelicki, N. Jazbec, J. Milek, M. Mlinaric-Rascan, I. Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients. Leukemia 2009; 23, 971-974 7. Ingelman-Sundberg, M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004; 25, 193-200 Memo